

February 23, 2024

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5th Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing

**National Stock Exchange of India Ltd.**

Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir/Ma'am,

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Inspired by our purpose and values, we are transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. At AstraZeneca, we believe that it is equally important to create value beyond the impact of our medicines. We are committed to building trust by demonstrating integrity, transparency and fairness in everything we do.

We wish to inform that due to several changes within the Board of Directors of the Company starting September 30, 2023, the Risk Management Committee was re-constituted on February 8, 2024 and that there was no meeting of Risk Management Committee held in the interim. The previous Risk Management Committee meeting was held on September 4, 2023. Further, we also wish to inform that the next meeting of Risk Management Committee with the re-constituted committee has already been scheduled for March 1, 2024.

In this regard, we would like to inform that BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”) have, vide their respective letters/emails dated February 22, 2024 imposed a fine of Rs. 2,17,120/- (Rupees Two Lakhs Seventeen Thousand One Hundred and Twenty only) each, on the Company under Regulation 21(2) of the SEBI Listing Regulations for not having the majority of the members of the Risk Management Committee from the Board of Directors as on December 31, 2023.

We further wish to inform that the Company will make necessary representations with both the stock exchanges for waiver of the above-mentioned penalty.

In this regard, the details as required under SEBI Listing Regulations read with Circular no. SEBI/HO/CFD/CFD-PoD-1/P-CIR//2023/123 dated July 13, 2023 are enclosed as **Annexure - I**.

Request you to kindly take the same on record.

Thanking you

**For AstraZeneca Pharma India Limited**

Manasa. R  
Company Secretary

**CORPORATE & REGD. OFFICE**  
AstraZeneca Pharma India Ltd.  
P. B. No. 4525, Block N1, 12th Floor,  
Manyata Embassy Business Park,  
Rachenahalli, Outer Ring Road,  
Bangalore - 560 045, INDIA

**TEL** : +91 80 6774 8000  
**FAX** : +91 80 6774 8857  
**CIN** : L24231KA1979PLC003563  
**WEB** : [www.astrazeneca.com/india](http://www.astrazeneca.com/india)

**FACTORY**  
12th Mile on Bellary Road  
Venkatala, Kattigenahalli Village  
Yelahanka  
Bangalore - 560 063  
INDIA

**TEL** : +91 80 6774 9000  
**FAX** : +91 80 2846 2208  
+91 80 6774 9628

### Annexure - I

<b>Name(s) of the Authority</b>	BSE Limited and National Stock Exchange of India Limited
<b>Nature and details of the action(s) taken, initiated or order(s) passed</b>	Fine of Rs. 2,17,120/- (Rupees Two Lakhs Seventeen Thousand One Hundred and Twenty only) by both BSE Limited and National Stock Exchanges of India Limited
<b>Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority</b>	February 22, 2024
<b>Details of the violation(s) / contravention(s) committed or alleged to be committed</b>	Regulation 21(2) of the SEBI Listing Regulations for not having the majority of the members of the Risk Management Committee from the Board of Directors
<b>Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible</b>	Nil except to the extent of penalty amount of Rs. 4,34,240/- (Rupees Four Lakhs Thirty Four Thousand Two Hundred and Forty only) imposed by both the Stock Exchanges.